Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Surgical Oncology

Building Your Care Team and Preparing for Your First Visit

At a Glance

For Malignant Peripheral Nerve Sheath Tumor (MPNST), treatment at a specialized sarcoma center with a multidisciplinary team is essential. Your core team should include specialized sarcoma surgeons, oncologists, and pathologists who collaborate to accurately diagnose and treat this rare cancer.

Because Malignant Peripheral Nerve Sheath Tumor (MPNST) is an exceptionally rare and complex cancer, the quality of your care team is the single most important factor in your treatment journey. National and international guidelines emphasize that these tumors should be managed by a multidisciplinary team (MDT) at a specialized sarcoma center [1][2].

Why Multidisciplinary Care is Essential

A multidisciplinary team is a group of doctors from different specialties who meet regularly to discuss your specific case. For a rare disease like MPNST, this collective expertise is vital for [1][3]:

  • Accurate Diagnosis: Ensuring a specialized pathologist confirms the diagnosis, as MPNST is frequently misidentified [4].
  • Coordinated Planning: Deciding the best sequence for surgery, radiation, and chemotherapy to maximize effectiveness and minimize side effects [5].
  • Specialized Expertise: Accessing advanced surgical techniques, such as limb-sparing surgery or complex nerve reconstructions [3].

Your Essential Care Team

Your “core” team at a specialized center should include specialists who focus primarily on sarcomas (cancers of the bone and soft tissue) [2][6]:

  1. Sarcoma Surgeon (Surgical Oncologist): Specializes in removing large or complex tumors while preserving as much function as possible.
  2. Sarcoma Medical Oncologist: An expert in using systemic treatments like chemotherapy and targeted therapies for sarcomas.
  3. Radiation Oncologist: Specializes in using high-energy beams to kill cancer cells and prevent local recurrence [7].
  4. Sarcoma Pathologist: A doctor who specializes in identifying rare bone and soft tissue tumors under the microscope [2].
  5. Musculoskeletal Radiologist: An expert in reading scans (MRI, CT, PET) specifically for bone and soft tissue issues.

Preparing for Your First Visit

When you visit a specialized center for the first time, you should bring physical copies of your records to ensure the team has everything they need to make a recommendation [4]:

  • Imaging Discs: Actual CD/DVD copies of your MRI, CT, and PET scans (not just the written reports).
  • Pathology Slides: The physical glass slides from your biopsy or previous surgery. The center’s own pathologist will want to review these [4].
  • Operative Reports: If you have already had a surgery, bring the detailed report written by the surgeon.
  • Family History: Especially details regarding Neurofibromatosis Type 1 (NF1) in yourself or blood relatives [8].

Vetting a Specialist

Don’t be afraid to ask direct questions. High-volume sarcoma centers are proven to have better outcomes for patients [9][10]. A qualified specialist will welcome your engagement and should be able to clearly explain why they are recommending a specific path for your care [11].

If you have NF1, it is also important to ask if the sarcoma team coordinates directly with a Neurofibromatosis clinic, as the management of NF1-associated tumors can require unique considerations [8][12].

Common questions in this guide

Why do I need a multidisciplinary team for MPNST?
A multidisciplinary team of sarcoma experts is crucial because MPNST is a rare and complex cancer that is frequently misidentified. This team collaborates to ensure an accurate diagnosis, coordinate the best sequence of treatments, and utilize advanced surgical techniques.
Which specialists should be on my MPNST care team?
Your core team at a specialized center should include a sarcoma surgeon, a sarcoma medical oncologist, a radiation oncologist, a specialized sarcoma pathologist, and a musculoskeletal radiologist.
What should I bring to my first appointment at a sarcoma center?
You should bring actual CD or DVD copies of your imaging scans (MRI, CT, PET), the physical glass pathology slides from your biopsy, any operative reports, and details about your family medical history.
Does having NF1 change how my MPNST care team should be structured?
Yes. If you have Neurofibromatosis Type 1 (NF1), your sarcoma team should ideally coordinate directly with a specialized neurofibromatosis clinic. NF1-associated tumors require unique management considerations that benefit from dedicated NF expertise.
How can I tell if a hospital is qualified to treat MPNST?
Look for a high-volume sarcoma center that regularly reviews cases using a multidisciplinary tumor board. You should ask the doctor directly how many MPNST patients they treat each year and if they have dedicated sarcoma pathologists on staff.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with MPNST does this center treat every year?
  2. 2.Will my case be reviewed by a multidisciplinary tumor board specifically for sarcomas?
  3. 3.Does your team include a pathologist who specializes specifically in bone and soft tissue sarcomas?
  4. 4.If I have NF1, how does the sarcoma team coordinate with neurofibromatosis specialists?
  5. 5.What experience does your surgical team have with nerve-sparing techniques for my specific tumor location?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).

    de Juan Ferré A, Álvarez Álvarez R, Casado Herráez A, et al.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021; (23(5)):922-930 doi:10.1007/s12094-020-02534-0.

    PMID: 33405052
  2. 2

    The Implications of an Unplanned Sarcoma Excision (the "Whoops" Operation).

    Grignol VP, Lopez-Aguiar AG

    The Surgical clinics of North America 2022; (102(4)):529-538 doi:10.1016/j.suc.2022.04.002.

    PMID: 35952685
  3. 3

    Oncologic safety of propeller flap and free flap in reconstruction after soft tissue sarcoma resection.

    Cha HG, Kang MK, Kim W, et al.

    Journal of surgical oncology 2020; (122(4)):787-794 doi:10.1002/jso.26076.

    PMID: 32596810
  4. 4

    The devastating impact of unresectable infectious undifferentiated pleomorphic sarcoma in the gluteal region: A case report.

    Goli R, Torabzadeh A, Hassanpour A, et al.

    International journal of surgery case reports 2024; (118()):109592 doi:10.1016/j.ijscr.2024.109592.

    PMID: 38552374
  5. 5

    Challenges in the Management of Complex Soft-Tissue Sarcoma Clinical Scenarios.

    Blank A, Fice MP

    The Journal of the American Academy of Orthopaedic Surgeons 2024; (32(3)):e115-e124 doi:10.5435/JAAOS-D-22-00865.

    PMID: 37852242
  6. 6

    Abdominal neoplastic manifestations of neurofibromatosis type 1.

    Dare AJ, Gupta AA, Thipphavong S, et al.

    Neuro-oncology advances 2020; (2(Suppl 1)):i124-i133 doi:10.1093/noajnl/vdaa032.

    PMID: 32642738
  7. 7

    Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy.

    Larrier NA, Czito BG, Kirsch DG

    Surgical oncology clinics of North America 2016; (25(4)):841-60.

    PMID: 27591502
  8. 8

    Uncommon Thigh Mass in Neurofibromatosis Type 1: Unveiling Aggressive Epithelioid Sarcoma.

    Gharbi MA, Limaiem F, Romdhane KB, et al.

    European journal of case reports in internal medicine 2024; (11(4)):004432 doi:10.12890/2024_004432.

    PMID: 38584901
  9. 9

    Improved survival for extremity soft tissue sarcoma treated in high-volume facilities.

    Abarca T, Gao Y, Monga V, et al.

    Journal of surgical oncology 2018; (117(7)):1479-1486 doi:10.1002/jso.25052.

    PMID: 29633281
  10. 10

    Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers?

    Lazarides AL, Kerr DL, Nussbaum DP, et al.

    Clinical orthopaedics and related research 2019; (477(4)):718-727 doi:10.1097/01.blo.0000533623.60399.1b.

    PMID: 30485258
  11. 11

    Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.

    Vaz-Salgado MA, Valverde-Morales C, Alvarez R, et al.

    Cancers 2025; (17(19)) doi:10.3390/cancers17193158.

    PMID: 41097686
  12. 12

    Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.

    Lohkamp LN, Parkin P, Puran A, et al.

    Frontiers in surgery 2022; (9()):886697 doi:10.3389/fsurg.2022.886697.

    PMID: 35592129

This page provides educational guidance on finding MPNST specialists and preparing for appointments. It does not replace professional medical advice or recommendations from your healthcare provider.

Get notified when new evidence is published on Malignant peripheral nerve sheath tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.